Objective:To explore severe acute mushroom poisoning with myocardial damage and the prognosis of the patient. Method: The clinical data of 18 cases of severe acute mushroom poisning treated from 1998 to 2007 in my hospital were collected and analyed retrospectively,and the biochemical indicators were compared. Results:18 cases of severe acute mushroom poisoning not only presented the gastrointestinal tract,liver,kidney toxicity,but particularly prominent cardiac toxicity,mainly as increase of myocardial enzymes, electrocardiogram changes and malignant arrhythmia. Given conventional detoxication,myocardial protection,anti-arrhythmia,blood purification treatment and so on,the patients showed a significant decline in serum concentrations of CR,BUN,ALT,AST,LDH,CK, CK-MB,and HBDH. The differences between pre-treatment and post-treatment indicators in both groups were significant (P

ObjectiveTo observe the efficacy of electroacupuncture with different wave patterns, sparse wave, intense wave, and sparse-intense wave, on the therapeutic efficacy in treating mild cognitive disorder after ischemic stroke.MethodSixty eligible patients were randomized into a sparse wave group, an intense wave group, and a sparse-intense wave group, 20 in each group. The three groups were given electroacupuncture at Baihui (GV20) and Shenting (GV24) in addition to the basic acupuncture treatment.The Mini-mental State Examination (MMSE) and Activities of Daily Living (ADL) were adopted for evaluation before and after the intervention by the same practitioner.ResultThe total effective rate was 55.0% in the sparse wave group, 65.0% in the intense wave group, and 90.0% in the sparse-intense wave group, and thedifferenceswere statistically significant among the three groups (P<0.05); afterintervention, the MMSE score increased significantly and ADL score decreased significantly in the three groups (P<0.01), and the inter-group differences were statistically significant after intervention(P<0.01).ConclusionElectroacupuncture with sparse wave, intense wave, or sparse-intense wave all can improve mild cognitive disorder, while the general therapeutic efficacy of sparse-intense wave is higher than sparse wave and intense wave.

Objective To explore a biodegradable drug?loaded composite scaffold and determine its bone regeneration and local long?term drug release ability. Methods In this study, RFP?loaded a novel poly (caprolactone)?b?poly (lactide?co?gly?colide)/β?TCP composite scaffold was produced using particle?leaching/freeze?drying technique. And the obtained composite scaffold was characterized by SEM, TGA, UV spectrophotometer, universal testing machine and so on. New Zealand rabbits were used to prepare bone defects, which was treated by the implantation of active artificial bone loaded with or without RFP. The blank group was untreated. Then the repairing effects of the materials were examined. Results The obtained porous scaf?fold has inter?connected and uniformly distributed pores, and the diameters of pores range from 200 μm to 300 μm. Many mi?cropores (10 μm to 50 μm) can be observed on the wall of macropores. The total porosity of the porous composite scaffold can reach as high as 83.4%; the β?TCP content of the scaffolds is 51.2%. Meanwhile, the addition of β?TCP avoided volume shrinkage compared with b?PLGC scaffold; Additionally, the porous composite scaffold has good compressive strength ( 240 kPa) and compressive modulus (1.0 MPa); And the drug loading of the scaffold was 3.2%,which could smoothly release drug for 63 days after a period of burst release for a week. All defects in the experimental groups were radiographically repaired. There were significant differences between the experimental groups and the control group. Conclusion RFP?loaded poly (cap?rolactone)?b?poly (lactide?co?glycolide)/β?TCP composite scaffold is expected to benefit in drug therapy and bone repair in the treatment of bone tuberculosis.

This study was aimed to investigate the effects of Chai-Hu Shu-Gan Tang (CHSGT) on levels of TNF-α and 5-HT in lithium chloride–pilocarpine caused epilepsy–depression comorbidity rat model, in order to discuss the intervention effect of CHSGT on TNF-α and 5-HT in epilepsy–depression comorbidity. The lithium chloride–pilocarpine caused epilepsy–depression comorbidity rat model was established. After 6 weeks of animal establishment, rats were randomly divided into 5 groups, which were citalopram group (A), physiological saline group (B), CHSGT high dose group (C), medium dose group (D), and low dose group (E). Intragastric administration was given for 4 weeks, twice a day. Before and after the treatment, RT-PCR was performed to detect hippocampal TNF-αlevels. Liquid chromatography-mass spectrometry was performed to detect hippocampal 5-HT levels. Both forced swimming test (FST) and saccharin preference test were carried out to monitor the depressive behaviors of rats. In the meantime, 24 hours a day video camera surveillance were performed to record the number of seizures of rats. The results showed that after treatment, the number of seizures of rats were significantly reduced, the accumulative immobility time in FST was shortened, and the consumption of sucrose increased significantly (P < 0.01) in group A, C and D. Compared with group B, after the treatment, the expressions of hippocampal TNF-α mRNA of rats in group A, C, D were distinctly downregulated, with the level of 5-HT significantly increased (P < 0.05,P < 0.01). Compared with group A, group C and D showed no significant changes. It was concluded that TNF-α played a role in the pathogenesis of epilepsy–depression comorbidity through mediating the level of 5-HT. High and medium doses of CHSGT can downregulate the expression of TNF-α mRNA in depression comorbidity of chronic temporal lobe epilepsy, increase 5-HT level, reduce the number of seizures of rats, and improve depressive behaviors.

Objective To prospectively compare the clinical efficacy between high versus low viscosity bone cement in percutaneous vertebroplasty (PVP) for severe osteoporotic vertebral compression fractures (OVCF).Methods A prospective study was conducted in 61 old patients with single severe OVCF who had sought medical attention in our hospital from August 2014 to October 2015.They were randomly assigned to group H (n =30) to receive PVP using high viscosity bone cement and group L (n =31) to receive PVP using low viscosity bone cement.The 2 groups were compared preoperatively and postoperatively in terms of visual analogue scale (VAS),Oswestry disability index(ODI),short Form-36 General Health Survey(SF-36),Kyphosis cobb's angle,height of the injured vertebra,and volume and leakage of bone cement.Results Significant improvements in VAS,ODI and SF-36 score were noted after operation in both groups,but there were no significant differences between the 2 groups (P ＞ 0.05).The 2 groups made significant improvements after operation in cobb's angle and height recovery rate of the injured vertebra;improvements in group H (14.7° ± 3.4° and 28％ ± 8％) were significantly greater than in group L (16.5° ± 2.5° and 22％ ± 7％) (P ＜ 0.05).The bone cement volumes in groups H and L were 4.94 ± 0.72 mL and 4.89 ±0.75 mL respectively,showing no statistically significant difference between the 2 groups (P ＞ 0.05).The leakage rate in group H was significantly lower than that in group L (13.33％ versus 35.48％) (P ＜ 0.05).All the patients were followed up for a mean time of 12 months (range,from 3 to 17 months).Cauda equina symptoms were observed in one patient and compression fracture of the adjacent vertebra happened in 2 patients,but no infection or pulmonary embolism occurred in any patient.Conclusions Both high viscosity cement PVP and low viscosity cement PVP can relieve back pain and improve quality of life in patients with severe OVCF,but the former may increase the efficacy and safety of PVP obviously in correction of cobb's angle,height restoration of the injured vertebra and reduction of cement leakage.

BACKGROUND: There are few reports about vascularization in the repairing of bone defect by heterogeneous deproteinized bone.OBJECTIVE: To verify the vascularization characteristics of heterogeneous deproteinized bone, tissue engineering scaffold material, in the repairing of large segmental bone defect.DESIGN, TIME AND SETTING: The randomized controlled animal experiment was performed between March 2005 and February 2007 at the Third Military Medical University, Chongqing, China.MATERIALS: Twenty-four 10 to 12 months old goats, weighing (22.5±2.5)kg, were obtained from the Animal Center of the Third Military Medical University, Chongqing, China. Segmental bone defects of 20 percent right tibia middle and inferior diaphysis of the 24 goats were made.METHODS: The 24 goats were divided into test group (n=16) and control group (n=8) randomly. Goats in test group were implanted with deproteinized bone+autologous MSCs+recombinant human bone morphogenetic protein-2 (rhBMP-2), goats in control group were implanted with autograft bone, and all fixed with half-ring sulcated external fixator. Every 4 weeks, 3 goats were killed after ink perfusing through femoral artery. A thick slice of new bone tissue was made to observe the vascularization.MAIN OUTCOME MEASURES: Vascularization of new bone observed through gross anatomy and imaging; vascular network of new bone observed through thick section, blood vessel amount and area measured by Image-proplus really image analysis software.RESULTS: No goat was infected or dead. Animal soft tissue was dyed black, blood vessels'size, ditribution and network structure were observed in subcutaneous tissue, fascia and periosteum. At 4 weeks postoperation implant margin became crude in the defect area; at 8 weeks postoperation transparent bone absorbing area of different size and irregular shape appeared; after 12 weeks postoperation high-dense calcification shadow appeared at the ends of defect bone and new bone connected with the ends completely. On 4 to 24 weeks postoperation, the blood vessel amount became large, alignment became regular, and their size and distribution became uniform. It showed no significant difference in blood vessel amount and area between 2 groups (P>0.05).CONCLUSION: Composite of heterogeneous deproteinized bone+autologous MSCs+rhBMP-2 has the same vascularization degree. of autogeneous bone graft in repairing of large segmental tibia defect.

Hypertrophic scar is the most common scar in clinic. Due to its high incidence, high rate of relapse and difficulty of complete removal, it has always been a big problem in burn and plastic surgery. In recent years, some scholars have found that botulinum toxin type A(BTX-A) can inhibit scar hyperplasia by reducing the tension around the wound, inhibiting the proliferation of fibroblasts, promoting their apoptosis, promoting the degradation of collagen fibers, reducing wound angiogenesis, reducing inflammation around the wound and other mechanisms. BTX-A has fewer adverse reactions and high safety. Additionally, its effect combined with triamcinolone acetonide and laser in treating scars is significant. Therefore, it has been widely used in the treatment of hypertrophic scars. In this paper, the research progress of BTX-A in the prevention and treatment of hypertrophic scar were reviewed in order to provide new ideas for the treatment of hypertrophic scar.

Hypertrophic scar is the most common scar in the clinic. Due to its high incidence, high rate of recurrence, and difficulty of complete removal, it has always been a major problem in the department of burn and plastic surgery. In recent years, some scholars have found that botulinum toxin type A(BTX-A) can inhibit scar hyperplasia by reducing the tension around the wound, inhibiting the proliferation of fibroblasts, promoting their apoptosis, promoting the degradation of collagen fibers, reducing wound angiogenesis, reducing inflammation around the wound and other mechanisms. BTX-A has fewer adverse reactions and high safety. Additionally, its effect combined with triamcinolone acetonide and laser in treating scars is significant. Therefore, it has been widely used in the treatment of hypertrophic scars. In this paper, the research progress of BTX-A in the prevention and treatment of hypertrophic scar was reviewed in order to provide new ideas for the treatment of hypertrophic scar.

Hypertrophic scar is the most common scar in the clinic. Due to its high incidence, high rate of recurrence, and difficulty of complete removal, it has always been a major problem in the department of burn and plastic surgery. In recent years, some scholars have found that botulinum toxin type A(BTX-A) can inhibit scar hyperplasia by reducing the tension around the wound, inhibiting the proliferation of fibroblasts, promoting their apoptosis, promoting the degradation of collagen fibers, reducing wound angiogenesis, reducing inflammation around the wound and other mechanisms. BTX-A has fewer adverse reactions and high safety. Additionally, its effect combined with triamcinolone acetonide and laser in treating scars is significant. Therefore, it has been widely used in the treatment of hypertrophic scars. In this paper, the research progress of BTX-A in the prevention and treatment of hypertrophic scar was reviewed in order to provide new ideas for the treatment of hypertrophic scar.

Hypertrophic scar is the most common scar in clinic. Due to its high incidence, high rate of relapse and difficulty of complete removal, it has always been a big problem in burn and plastic surgery. In recent years, some scholars have found that botulinum toxin type A(BTX-A) can inhibit scar hyperplasia by reducing the tension around the wound, inhibiting the proliferation of fibroblasts, promoting their apoptosis, promoting the degradation of collagen fibers, reducing wound angiogenesis, reducing inflammation around the wound and other mechanisms. BTX-A has fewer adverse reactions and high safety. Additionally, its effect combined with triamcinolone acetonide and laser in treating scars is significant. Therefore, it has been widely used in the treatment of hypertrophic scars. In this paper, the research progress of BTX-A in the prevention and treatment of hypertrophic scar were reviewed in order to provide new ideas for the treatment of hypertrophic scar.